Posted: 6th May 2025
4D Medical announced a significant agreement with Intermountain Health, a leading healthcare network based in Salt Lake City, Utah. The agreement saw 4D Medical’s advanced pulmonary hypertension analysis algorithm, powered by artificial intelligence (AI), deployed across Intermountain Health’s extensive network of 33 hospitals, 400 clinics, and nearly 4,000 physicians.
4D Medical said “the first year’s payment by Intermountain Health to Nuance is fixed, at a price that represents only a small volume of scans … however, in future years the payments will build to the number of scans in use across the 33 hospitals in the system, thereby representing a significant opportunity. The financial terms of the contract remained undisclosed.
A spokesperson for 4D Medical highlighted that the algorithm, developed by its subsidiary Imbio, received FDA 510(k) clearance on August 27, 2024. This clearance marked a critical milestone, enabling the algorithm’s use in clinical settings to assess pulmonary hypertension secondary to pulmonary embolism. The technology measured right ventricle and main pulmonary artery diameters, along with clinically relevant ratios, to identify pulmonary hypertension caused by thrombus-related pulmonary embolism.
The partnership with Intermountain Health represented the first major deployment of 4D Medical’s algorithm within a large, global, integrated health network. The contract was secured through a distribution deal with Microsoft-owned Nuance Communications, which provided AI-driven clinical documentation and diagnostic imaging solutions to healthcare providers across the United States.
In 2023, 4D Medical acquired Imbio, an imaging company based in Minneapolis, Minnesota, for $US25 million ($A38.6 million). This acquisition bolstered 4D Medical’s capabilities in developing cutting-edge imaging solutions.
Following the announcement, 4D Medical’s shares rose by half a cent, or 1.7 percent, to 30 cents, with 2.8 million shares traded.
